Aliceblue ANTInstall and trade smarter everywhere
Complete IPO details, including price band, financials, subscription status, and key insights.
Participate in the Sai Parenteral's Ltd IPO with full transparency. Review issue details, company fundamentals, and financial performance, and apply securely through Alice Blue.
Key metrics and details at a glance.
Price Band
₹392
Per ShareLot Size
38 Shares
Minimum Investment
₹14,896
Issue Size
₹408.79 Cr
Face Value
₹5
Per ShareIPO Type
Book Building
Retail Quota
35%
QIB Quota
50%
NII Quota
15%
Important dates for your applying strategy.
Business model, operations, and market positioning.
Promoter Holding (Pre-Issue)
61.23%
Promoter Holding (Post-Issue)
51.16%
Issue Type
Book Building
ISIN
INE0H9F01037
The Company is a diversified pharmaceutical formulations company with capabilities in research, development and manufacturing. The Company is in the business of (i) Branded Generic Formulations and (ii) Contract Development and Manufacturing Organisation ("CDMO") products and services for the domestic and international markets. The Company's portfolio includes formulation products across various therapeutic areas like cardiovascular, neuropsychiatry, anti-diabetic, respiratory health, antibiotics, gastroenterology, vitamins, minerals and supplements (VMS), analgesics, and dermatology with offerings across dosage forms such as injectables, tablets, capsules, liquid orals and ointments. In the injectables segment, it has capabilities in sterile manufacturing for critical care and antibiotics, which are delivered through dry powder injections, pre-filled syringes, ampoules, and vials.
The Indian pharmaceutical industry is the world's third largest by volume and was estimated at $62 billion in 2025. It is expected to grow at a CAGR of 11.2% to reach $146 billion by 2033. The Indian drug formulation market, estimated at $47 billion in 2025, is projected to reach $109 billion by 2033, reflecting a robust CAGR of 11.2% over the period. Indian CDMOs are increasingly participating in larger parts of the pharma value chain, from drug discovery to commercialisation across multiple geographies, in response to evolving trends in the global pharmaceutical industry. Indian CDMO segment to sustain its strong growth trajectory over the next 10 years.
Revenue, profit after tax and total assets across the last 3 reported financial years.
Amount in ₹ crore
How the company plans to utilize IPO proceeds.
The funds raised through this IPO will be used for:
Initial public offer of 10,428,288 equity shares of face value of Rs. 5 each ("Equity Shares") of Sai Parenteral's Limited ("Company" or "Issuer") for cash at a price of Rs. 392 per equity share (Including a Share Premium of Rs. 387 Per Equity Share) ("Offer Price") aggregating to Rs. 408.79 Crore comprising a fresh issue of 7,270,408 equity shares of face value of Rs. 5 each aggregating to Rs. 285 Crore by the company ("Fresh Issue") and an offer for sale of 3,157,880 equity shares of face value of Rs. 5 each aggregating to Rs. 123.79 Crore ("Offered Shares") by investor selling shareholders (such sale, the "Offer For Sale", and together with the fresh issue, the"Offer"). The offer shall constitute 23.60% of the post-offer paid up equity share capital of the company. Price Band: Rs. 392 per equity share of face value of Rs. 5 each. The floor price is 78.40 times the face value of the equity shares. Bids can be made for a minimum of 38 equity shares of face value of Rs. 5 each and in multiples of 38 equity shares of face value of Rs. 5 each thereafter.
*Subject to approvals and market conditions.
Key competitive advantages and factors to consider before investing.
Live demand across investor categories.
Track real-time subscription levels:
*Real-time data subject to exchange updates
The Company was originally incorporated as `Sai Parenteral's Private Limited', a private limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated January 12, 2001, issued by the Registrar of Companies, Andhra Pradesh at Hyderabad. Thereafter, the Company was converted into a public limited company pursuant to resolution of its Board dated December 24, 2021 and a special resolution of its Shareholders dated January 05, 2022, and consequently, the name of our Company was changed to `Sai Parenteral's Limited' and a fresh certificate of incorporation consequent upon conversion to public limited company dated January 17, 2022, was issued to our Company by the RoC.
Wholesaler and Retailer
Amount in ₹ crore
Amount in ₹ crore
Figures in ₹ crore, on a consolidated basis, as reported for FY24 to FY26.